vTv Therapeutics Inc.
vTv Therapeutics Inc. is a U.S.-based biopharmaceutical company organized as a holding company with operations conducted through vTv Therapeutics LLC. The company focuses on discovering and developing drug candidates, with cadisegliatin as its principal program in diabetes and additional assets licensed from third parties and collaborators.
Fiscal year 2025 · change from previous year
Development 2020–2025
Business
Share of revenueDrug programs in human clinical development, including cadisegliatin for diabetes.
Compounds and programs licensed from partners for discovery and development.
Up-front fees, development milestones, and research fees from partners.
Customers
vTv Therapeutics does not sell commercial drugs today; its economic counterparties are pharmaceutical partners, licensees, and collaborators that fund development through licenses, milestones, and research agreements. In a future commercialization scenario, its end customers would be patients and healthcare providers in diabetes and related metabolic disease markets. The company’s current business model is therefore partner-driven, with value created through clinical progress and intellectual property rights rather than product sales.
Companies or institutions that license programs and pay milestones, up-front fees, or research support.
Organizations involved in running or supporting trials for cadisegliatin and related programs.
Patients who would use an approved therapy such as cadisegliatin if development succeeds.
Physicians and reimbursement decision-makers who would influence adoption of any approved product.
Strategy
The company’s strategy centers on advancing cadisegliatin through clinical development and securing the regulatory evidence needed for later-stage studies and potential approval. It also uses partnerships and licensing to fund development, broaden geographic reach, and preserve optionality around future commercialization. Because it has no approved products, execution depends on trial design, partner alignment, and maintaining intellectual property rights.
Clinical proof is the main driver of value for a development-stage biopharma company.
Milestones, up-front fees, and research payments support operations before product sales exist.
Broader geography can support enrollment, regulatory strategy, and future market access.
Geography
vTv Therapeutics is headquartered in the United States, but its development model is international because its programs and partnerships can span multiple regions. The company has disclosed planned clinical activity in the Middle East for type 2 diabetes and expects future registrational studies for type 1 diabetes to be international as well. As a development-stage biopharma company, geography matters mainly through trial execution, regulatory pathways, and partner reach rather than manufacturing footprint.
Risks
The company faces the core risks of development-stage pharmaceuticals: clinical failure, regulatory delays, safety findings, and uncertainty over eventual approval. It also depends on third-party manufacturers and collaborators, so supply disruption, partner termination, or weak financing access could slow or stop development. If approved, commercialization would still depend on reimbursement, market acceptance, and competition from better or faster-moving diabetes therapies.
- Clinical trial delay or failureImpact: CriticalLikelihood: Medium
Development-stage assets can lose value if enrollment, endpoints, or safety results disappoint.
Exposure: Cadisegliatin registrational and Phase 2 studies
- Regulatory approval riskImpact: CriticalLikelihood: Medium
The company has no approved products and must satisfy FDA and other regulators.
Exposure: NDA/clinical development pathway
- Third-party manufacturing dependenceImpact: HighLikelihood: Medium
The company does not own manufacturing facilities and relies on external suppliers.
Exposure: Clinical supply and future commercial supply
- Partner and funding dependenceImpact: HighLikelihood: Low
Milestone and collaboration revenue depends on counterparties and contract continuity.
Exposure: License agreements and research collaborations
- Commercialization and reimbursement riskImpact: MediumLikelihood: Medium
Even if approved, uptake depends on pricing, payor coverage, and competition.
Exposure: Diabetes treatment market
Accounting
Judgemental itemsRevenue is driven by contract terms and achievement of development milestones, not product sales.
Impact: Can create large quarter-to-quarter swings in reported revenue
Clinical trial design, enrollment, and external study costs drive expense recognition.
Impact: Affects operating loss trends and comparability across periods
vTv Therapeutics Inc. consolidates vTv LLC under the VIE model.
Impact: Determines which assets, liabilities, and results appear in the financial statements
A common non-cash expense for development-stage biotech companies.
Impact: Can materially affect operating expenses and equity balances
Similar listed companies
Publicly listed companies with a comparable business focus.
Cadrenal Therapeutics, Inc.
CVKD · Pharmaceutical Preparations
Ventyx Biosciences, Inc.
Pharmaceutical Preparations
Gain Therapeutics, Inc.
GANX · Pharmaceutical Preparations
Viking Therapeutics, Inc.
VKTX · Pharmaceutical Preparations
Viking Therapeutics is a U.S.-based clinical-stage biopharmaceutical company developing novel therapies for metabolic and endocrine disorders.
Vistagen Therapeutics, Inc.
VTGN · Pharmaceutical Preparations
Vistagen Therapeutics is a U.S.-based clinical-stage biopharmaceutical company focused on neuroscience disorders.
MetaVia Inc.
MTVA · Pharmaceutical Preparations
Last updated: 24/09/2026